Clinical Trials Logo

Clinical Trial Summary

This trial is conducted in patients with the recurrent lesion(s) post-surgery or the untreated mCRC. After stratification with respect to ECOG PS score, chemo regimen, primary tumor location and KRAS and BRAF genotype (complete wild-type/primal type), eligible patients are randomized into two arms at 1:1 ratio to receive HLX04 (Arm A) or Bevacizumab (Arm B) in combination with one of the protocol-defined chemotherapies, modified FOLFOX6 (mFOLFOX6) or XELOX for mCRC until disease progression (PD) or unacceptable toxicity or achieving an operable contingency, whichever occurs first.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03511963
Study type Interventional
Source Shanghai Henlius Biotech
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 9, 2018
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT02069704 - Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Phase 1
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. Phase 1
Completed NCT00594984 - Phase I/II Combination With Irinotecan- Erbitux Phase 1/Phase 2
Recruiting NCT03829462 - Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients Phase 3
Recruiting NCT04856787 - A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC Phase 2/Phase 3
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Completed NCT05420909 - A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
Not yet recruiting NCT06089330 - A Study of JMT101 in Patients With Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Active, not recruiting NCT05839951 - An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions